MA28973B1 - Compose heterocyclique fusionne - Google Patents

Compose heterocyclique fusionne

Info

Publication number
MA28973B1
MA28973B1 MA29533A MA29533A MA28973B1 MA 28973 B1 MA28973 B1 MA 28973B1 MA 29533 A MA29533 A MA 29533A MA 29533 A MA29533 A MA 29533A MA 28973 B1 MA28973 B1 MA 28973B1
Authority
MA
Morocco
Prior art keywords
optionally substituted
bonded
compound
fusioned
heterocyclic compound
Prior art date
Application number
MA29533A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Takahiko Taniguchi
Hiroshi Banno
Masaki Seto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA28973B1 publication Critical patent/MA28973B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composé représenté par la formule (I) [où W représente C(R1) ou N ; A représente de l'aryl substitué par option ou de l'hétéroaryl substitué par option ; X1 représente -NR3-Y1-, O-, -SO-, SO2-, ou -CHR3- (où R3 représente de l'hydrogène ou, par substitution, un ensemble d'hydrocarbone aliphatique, à condition que R3 puisse être lié à A pour former une structure annulaire substituée par option) ; R1 représente de l'hydrogène ou un ensemble substitué par option lié par un atome de carbone, de nitrogène ou d'oxygène ; et R2 représente de l'hydrogène ou un ensemble substitué par option lié par un atome de carbone ou de sulfure, pourvu que R2 puisse être lié à R1 ou R3 afin de former une structure annulaire substituée par option] ou un sel du composé. Il est également présenté un inhibiteur tyrisinkinase ou agent thérapeutique préventif des cancers, chacun comprenant le composé ou un dérivé de celui-ci.
MA29533A 2004-06-02 2006-12-15 Compose heterocyclique fusionne MA28973B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004165050 2004-06-02
JP2005058231 2005-03-02

Publications (1)

Publication Number Publication Date
MA28973B1 true MA28973B1 (fr) 2007-11-01

Family

ID=35462874

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29533A MA28973B1 (fr) 2004-06-02 2006-12-15 Compose heterocyclique fusionne

Country Status (18)

Country Link
US (4) US7507740B2 (fr)
EP (1) EP1752457B1 (fr)
JP (2) JP4134227B2 (fr)
KR (1) KR101194622B1 (fr)
AU (1) AU2005250285B2 (fr)
BR (1) BRPI0511768A (fr)
CA (1) CA2569016C (fr)
CR (1) CR8827A (fr)
GE (1) GEP20105024B (fr)
IL (1) IL179414A (fr)
MA (1) MA28973B1 (fr)
ME (1) MEP8409A (fr)
MX (1) MXPA06013996A (fr)
NO (1) NO20066015L (fr)
NZ (1) NZ551938A (fr)
RU (1) RU2389731C2 (fr)
TW (1) TWI392679B (fr)
WO (1) WO2005118588A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US7932257B2 (en) * 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
EA200970353A1 (ru) 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
US20100004238A1 (en) 2006-12-12 2010-01-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
US7776857B2 (en) * 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
JP5603770B2 (ja) * 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
RU2010101416A (ru) 2007-06-19 2011-07-27 Такеда Фармасьютикал Компани Лимитед (Jp) Профилактическое/лекарственное средство от рака
EP2255830A1 (fr) * 2008-03-03 2010-12-01 Takeda Pharmaceutical Company Limited Médicament concomitant
EP2253633A4 (fr) * 2008-03-12 2012-02-29 Takeda Pharmaceutical Composé hétérocyclique fusionné
CA2716856C (fr) * 2008-03-20 2013-02-19 Amgen Inc. Modulateurs d'aurora kinase et procede d'utilisation
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
TW201016703A (en) * 2008-09-26 2010-05-01 Takeda Pharmaceutical Prevention and treatment of cancer with LKB1 non-expression (deletion or mutation)
TW201016704A (en) * 2008-09-26 2010-05-01 Takeda Pharmaceutical Prevention and treatment of cancer with RAS gene mutation
WO2010036910A1 (fr) * 2008-09-26 2010-04-01 Yoshikazu Ohta Protection cardiaque par administration d'un activateur de protéine kinase activée par amp
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
CN102369205B (zh) 2009-01-30 2014-10-29 武田药品工业株式会社 稠环化合物和其用途
US8614208B2 (en) * 2009-08-26 2013-12-24 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011040212A1 (fr) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Agent thérapeutique pour une tumeur cérébrale
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011141474A1 (fr) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Nouveaux antagonistes des récepteurs ccr2, procédé de production associé et application comme médicaments
WO2011144501A1 (fr) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Antagonistes du récepteur ccr2 et leurs utilisations
WO2011147772A1 (fr) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Antagonistes du récepteur ccr2
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
CA2760174A1 (fr) * 2011-12-01 2013-06-01 Pharmascience Inc. Inhibiteurs de proteines kinases et leurs utilisations
AP2013007253A0 (en) * 2011-04-21 2013-11-30 Origenis Gmbh Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
EP2731941B1 (fr) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Antagonistes ccr2, nouveaux et sélectifs
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
RS58361B1 (sr) * 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2015162515A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
PL3137470T3 (pl) 2014-05-01 2021-10-11 Novartis Ag Związki i kompozycje jako agonisty receptora toll-like 7
ES2908150T3 (es) 2014-05-01 2022-04-27 Novartis Ag Compuestos y composiciones como agonistas del receptor de tipo Toll 7
PT3317270T (pt) 2015-07-02 2020-08-24 Centrexion Therapeutics Corp (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona
EP3368092B9 (fr) 2015-10-29 2020-07-29 Novartis AG Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3591845B1 (fr) * 2018-07-05 2023-08-09 Universite De Bretagne Sud Méthodes et appareils de triage pour traitement élémentaire de noeuds de contrôle pour décodage de codes non-binaires par passage de messages
WO2020118183A1 (fr) * 2018-12-06 2020-06-11 Kapoor Tarun M Bicycles de 2,4-diaminopyrimidine pour le traitement du cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS554116B2 (fr) * 1971-08-20 1980-01-29
DK0705263T3 (da) * 1993-06-21 1997-05-05 Merrell Pharma Inc Carbocycliske nukleoside midler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
JP3290666B2 (ja) * 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA001595B1 (ru) * 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
EA199900021A1 (ru) * 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
WO1998007726A1 (fr) * 1996-08-23 1998-02-26 Novartis Ag Pyrrolopyrimidines substituees et procede pour leur preparation
JPH10130258A (ja) 1996-10-10 1998-05-19 Eli Lilly & Co ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
WO1998023613A1 (fr) * 1996-11-27 1998-06-04 Pfizer Inc. Derives de pyrimidines bicycliques fusionnes
CN1264381A (zh) 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000005234A1 (fr) * 1998-07-22 2000-02-03 Suntory Limited INHIBITEURS DE NF-λB CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
WO2001018170A2 (fr) * 1999-08-26 2001-03-15 Plant Research International B.V. Inhibition conditionnelle de multiplication vegetative
DE60225127T2 (de) 2001-04-30 2009-02-19 Glaxo Group Ltd., Greenford Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
RU2003134646A (ru) 2001-04-30 2005-04-20 Глэксо Груп Лимитед (GB) Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
BRPI0410720A (pt) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2006020985A (ja) 2004-07-05 2006-01-26 Kiyoshi Owada 微小孔を用いた入浴剤用炭酸ガス拡散装置
ES2438017T3 (es) * 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
EA200970353A1 (ru) * 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
RU2010101416A (ru) * 2007-06-19 2011-07-27 Такеда Фармасьютикал Компани Лимитед (Jp) Профилактическое/лекарственное средство от рака
EP2253633A4 (fr) * 2008-03-12 2012-02-29 Takeda Pharmaceutical Composé hétérocyclique fusionné

Also Published As

Publication number Publication date
IL179414A0 (en) 2007-05-15
JP4134227B2 (ja) 2008-08-20
BRPI0511768A (pt) 2008-01-08
AU2005250285B2 (en) 2011-08-18
US20070244132A1 (en) 2007-10-18
US20090203717A1 (en) 2009-08-13
WO2005118588A1 (fr) 2005-12-15
MXPA06013996A (es) 2007-02-08
US20090018335A1 (en) 2009-01-15
EP1752457A1 (fr) 2007-02-14
JP4937172B2 (ja) 2012-05-23
EP1752457A4 (fr) 2010-05-26
AU2005250285A1 (en) 2005-12-15
NZ551938A (en) 2010-07-30
RU2389731C2 (ru) 2010-05-20
GEP20105024B (en) 2010-06-25
CR8827A (es) 2007-04-20
EP1752457B1 (fr) 2014-03-19
TWI392679B (zh) 2013-04-11
JPWO2005118588A1 (ja) 2008-04-03
KR101194622B1 (ko) 2012-10-29
JP2008247907A (ja) 2008-10-16
TW200611907A (en) 2006-04-16
CA2569016A1 (fr) 2005-12-15
KR20070026695A (ko) 2007-03-08
US20090029973A1 (en) 2009-01-29
US7507740B2 (en) 2009-03-24
US8178543B2 (en) 2012-05-15
NO20066015L (no) 2007-02-13
RU2006147267A (ru) 2008-07-20
IL179414A (en) 2013-11-28
MEP8409A (en) 2011-12-20
CA2569016C (fr) 2012-11-27

Similar Documents

Publication Publication Date Title
MA28973B1 (fr) Compose heterocyclique fusionne
Bell et al. 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency
MA27626A1 (fr) Nouveaux derives de 2-pyridinecarboxamide
ATE320252T1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäuream d derivate als hsp90 inhibitoren zur behandlung von krebs
MXPA05009059A (es) Derivados de heteroarilcarbamoilbenceno.
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA32642B1 (fr) Amides utiles en therapie
HUP0302960A2 (hu) Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
Pecic et al. Synthesis and structure–activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors
Suryapeta et al. Synthesis, biological evaluation, and docking study of a series of 1, 4‐disubstituted 1, 2, 3‐triazole derivatives with an indole‐triazole‐peptide conjugate
FR2642759B1 (fr) Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
Lindel et al. Synthesis of the Marine Natural Product N α-(4-Bromopyrrolyl-2-carbonyl)-l-homoarginine, a Putative Biogenetic Precursor of the Pyrrole− Imidazole Alkaloids
Woods et al. Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors
Böhm et al. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors
Tsotinis et al. Mapping the melatonin receptor. 7. Subtype selective ligands based on β-substituted N-acyl-5-methoxytryptamines and β-substituted N-acyl-5-methoxy-1-methyltryptamines
Naumov et al. Experimental and theoretical vibrational study of isatin, its 5-(NO2, F, Cl, Br, I, CH3) analogues and the isatinato anion
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
CA2326710A1 (fr) Nouveaux derives de dihydrofuro-¬3,4-b|quinolein-1-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
Van de Walle et al. Synthesis of novel nitroxoline analogs with potent cathepsin B exopeptidase inhibitory activity
Hirst et al. Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight ‘molecular budget’
deSolms et al. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase
ATE320420T1 (de) Verfahren zur herstellung von optisch aktiven naphthalinderivaten und darin eingesetzte optische resolver